A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug
ramucirumab in combination with docetaxel in participants with urothelial cancer who failed
prior platinum-based therapy.